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Irritable Bowel Syndrome (IBS) is the most prevalent functional gastrointestinal 
(GI) disease in the western world today. There are multiple subtypes of IBS and the 
symptoms of the disease vary drastically. The main types of IBS are IBS with 
constipation (IBS-C), IBS with diarrhea (IBS-D) and mixed IBS (IBS-M). Because of the
commonality of this disease, there are a wide array of treatments that have been used and 
are currently being used to treat patients suffering with IBS symptoms. These treatments 
vary in their efficacy, with some being much more effective than others for the specific 
subtypes of the disease. However, as technological advances increase and the root cause 
and pathophysiology of IBS is discovered, more efficacious treatments are also being 
discovered. The most common treatments used today include but are not limited to 
probiotic supplements, limited diets such as the FODMAP diet, antibiotics and 
antidepressants, and psychological interventions such as Cognitive Behavioral Therapy 
(CBT) and hypnosis. New promising treatments include Fecal Microbiota Transplants 
(FMT) and individualized medicine. 
iv
The pathophysiology of IBS has not yet been completely elucidated but the 
literature is clear on the fact that there are microbiome changes in patients with IBS. 
Many of the treatments that have high rates of success address the microbiome changes. 
The future of IBS treatments may depend on the gut microbiota and establishing a new 
gut environment through a variety of methods. Moreover, many of the current treatments 
treat this aspect of IBS as well. IBS is not a disease exclusive to the gut and is thought to 
influence and be influenced by outside stress and neurotransmitters such as serotonin. 
The research on IBS treatments indicates that there is no one treatment that is the most 
effective but rather that individuals need to work with health professionals to find a 
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Irritable Bowel Syndrome (IBS) is the most commonly diagnosed gastrointestinal 
(GI) disease in the United States today. Approximately 20% of Americans are diagnosed 
with IBS (Camilleri et. al., 1997).  IBS is considered a functional gastrointestinal disorder
which is characterized by a change in gut motility, microbiome disturbances, decreased 
immune functioning, and visceral hypersensitivity (Drossman 2016). 
This disease is characterized by a vast array of symptoms, but most people fall 
into four different camps, IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), 
mixed IBS (IBS-M), and unclassified IBS (IBS-U). To be diagnosed with IBS, Rome III 
criteria requires the individual to have at least three days per week of abdominal 
discomfort associated with change in frequency of bowel movements, change in bowel 
movement form, and/or improvement upon making a bowel movement for at least three 
months. The diagnosis of what type of IBS the patient has is also predominately made 
upon the Bristol stool chart, a chart that characterizes the form, texture and consistency of
the stool. Table 1 shows the Bristol Stool Chart which allows physicians to diagnose 
individuals into an appropriate subtype of IBS (Drossman, 2016). 
Table 1: Bristol Stool Chart. *
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*This chart characterizes the form of stool and allows physicians separate individuals 
with IBS into appropriate subcategories (IBS-C, IBS-D, IBS-M). Smaller numbers 
indicate IBS-C whereas larger numbers indicate IBS-D. Table from (Drossman, 2016).
There are also believed to be two more categories regarding the origin of IBS, 
nonspecific and post-infectious IBS (PI-IBS) meaning the onset of disease followed a 
bout of acute gastroenteritis (Thabane and Marshall, 2009). The commonality of this 
disease may be due to the fact that it is a disease of exclusion meaning that most doctors 
diagnose IBS when there is an absence of symptoms belonging to other common 
gastrointestinal diseases such as Irritable Bowel Disease (IBD). 
Essentially, the diagnosis of IBS relies on a change in digestive patterns or a 
predominately abnormal digestion. Many symptoms of IBS-C and IBS-D overlap with 
each and other common GI diseases such as IBD. Common symptoms of these GI 
diseases include bloating, cramping and overall discomfort of the lower abdominal area
(Talley et al., 2003). Current research suggests the pathophysiology of IBS may be due to
a variety of factors such as lifestyle, diet, underlying immune dysregulation, and a gut 
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microbiota imbalance (Zhou et al., 2019). This dysregulation and imbalance in the gut 
microbiome lead to dyspepsia which in turn leads to inflammation. This inflammation 
can leak into the brain via the gut brain axis and lead to other diseases and symptoms 
such as depression (Daulatzai, 2014). 
Understanding the mechanisms and symptoms of this disease are crucial to 
alleviating not only GI disturbances but also other imbalances brought about by the 
various axes from the gut. Due to the complicated pathophysiology of IBS, there are 
differing treatments and remedies that are unique to individual’s symptoms. Some 
address lifestyle while others address the gut-brain axis. Figure 1 shows several areas that
are thought to cause IBS symptoms and thus areas implemented in therapies that help to 
alleviate these symptoms. 
Figure 1: Various causes and bodily functions implemented in IBS. GI-related 
influences refer to microbiome changes in which the microbiome is altered which can 
3
lead to increased inflammation and can increase IBS symptoms. Dietary influence refers 
to common GI irritants in those with IBS such as FODMAPs and gluten. Dietary 
intervention is often employed in those who have issues with these food categories. 
Central nervous system and psychological association refers to the gut-brain axis and 
outside influences such as stress and anxiety. Genetic and epigenetic influence deals with 
the genes and are often out of the patient’s control. These areas are often implemented in 
treatments for IBS. Figure from (Chong et al., 2019).
Microbiome changes in IBS 
Most treatments for IBS today take advantage of the fact that the manifestation of 
IBS is associated with changes to the microbiome. Exact changes to the microbiome are 
unknown and differ among humans. Research studies have shown that alterations to the 
microbiome affect the gut-brain axis, a key pathway in IBS (Quigley, 2018). Figure 1 
shows the pathway between altered microbiome and the consequences for the gut-brain 
axis in IBS patients. Common findings of microbiome changes show there are decreased 
level of Lactobacillus and Bifidobacterium in patients suffering with IBS-D and a higher 
level of methanogens in IBS-C (Liu et al., 2017). Moreover, other research found that the 
amount of Proteobacteria and Firmicutes were higher in the microbiomes of those with 
IBS-D as compared to control subjects whereas Actinobacteria and Bacteroides were 
significantly lower in these patients as compared to control (Krogius-Kurikka et al., 
2009).
4
Figure 2: Changes in the microbiome affect the gut-brain axis and immunity 
systems. Microbiome disruption alters various central nervous system processes such as 
stress and cognition and vice versa. With a normal, healthy gut microbiome, immune 
function is intact as well is the gut barrier and the central nervous system is able to 
respond accordingly and in a non-altered way. These systems are reciprocal and not do 
not act independently of one another. Figure from (Quigley, 2018).
The results from microbiome analyses can have significant implications in many 
different treatment options for IBS including use of probiotics, diet and fecal transplants. 
These results also show how individual treatments have to be tailored to the individual 
nature of patients’ microbiomes and their respective alterations due to IBS. Each 
microorganism has specific roles within the microbiome so manipulating them and 
reestablishing a healthy homeostasis is the underlying mechanism in many different 
treatment options for IBS.
5
Aims
This thesis includes an overview of the many types of treatments for Irritable 
Bowel Syndrome (IBS). The introduction will give a background into IBS and its variety 
of symptoms. The thesis will first outline the growing field of fecal transplants as a 
means for treatment. Then it will reveal the varying diets and supplements, including 
probiotics that have been used to treat IBS. Next, it will explore antibiotics and other 
drugs that are prescribed for both symptoms and the underlying causes of IBS. Then, 
therapy and psychological treatments will be addressed as many believe that IBS can be 
brought on by stress and lifestyle factors. Finally, the future for treatments of IBS will be 
discussed.
Fecal Transplants
Perhaps the newest treatment for IBS is fecal microbiome transplants (FMT). 
FMT were first implemented in patients with Clostridium difficile and showed a 
significant decrease in patients’ symptoms compared to treatment with antibiotics due to 
changes in the gut microbiome (van Nood et al., 2013). Because IBS is characterized by a
change in the gut microbiota, which it has in common with C. difficile infections, fecal 
transplants aim to implement new, healthier and more diverse gut microbiota in IBS 
patients. The gut microbiota is home to trillions of organisms which can have various 
roles in every system within the human body (Chong et al., 2019). When the ratio of the 
various organisms including fungi, archaea, and eukaryotes are disturbed, it can lead to 
dysbiosis. This dysbiosis is characterized by changes in gut motility, impaired nutrient 
absorption, pain and bloating. In individuals who have increased permeability between 
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their endothelial cells within their small intestines, this dysbiosis can lead various 
diseases such as IBS, and IBD (Tamboli et al., 2004).  Although fecal transplantation is a 
very new treatment for IBS it has been well established that the gut microbiome is altered
in patients suffering from IBS and this alteration can lead to a variety of disease, not just 
GI in origin (Kassinen et al., 2007). 
Understanding these changes is crucial to creating a successful treatment plan as 
these microbiome disturbances may be the underlying mechanism to IBS. Because the 
microbiome controls many mechanisms in the body, establishing a new microbiome with 
a different ratio of microorganisms is the idea behind FMT and may be beneficial for not 
just IBS but other diseases as well.
An FMT involves transplanting feces with specific microbiota from healthy 
individuals into an individual who has been diagnosed with IBS or some other disease. 
The interplay between the new microbiota and the host is thought to seal up the gaps 
within the small intestine and establish a healthier ratio of gut microorganisms whose aim
is to relieve IBS symptoms. FMTs are especially interesting today because they do not 
confer antibiotic resistance and allow the whole gut microbiome to be influenced. 
Moreover, because of the nature of this procedure, FMT can help cure or alleviate 
symptoms of diseases that have not yet been diagnosed (Borody et al., 2014). FMTs have 
minimal risk and minimal side effects due to the lack of antibiotics which makes it even 
more appealing to some. 
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Because this method of treating IBS is so new, research is still needed to form an 
appropriate conclusion about its efficacy. However, research has indicated that fecal 
transplants do change the host’s gut microbiome (Aroniadis et al., 2019). Whether or not 
these changes result in improved lifestyle factors in patients with IBS is still being 
researched. These results also indicate differences among IBS categories. The efficacy of 
the procedures depends on the both donors’ microbiome and recipients’ response to this 
new microbiome. 
Because the microbiome is so vast, research is still being done to determine which
microorganisms make up a healthy microbiome and which organisms should be used to 
treat certain diseases. Moreover, “superdonors” have now been identified as specific 
people who have a certain microbiome that has been shown to positively influence 
others’ microbiomes. However, superdonors’ microbiomes are not universally efficacious 
but rather they are specific to a certain disease. This means that for a specific disease, 
there are certain microorganisms that some superdonors possess that have been shown to 
improve symptoms but will not improve symptoms of other diseases (Wilson et al., 
2019).  
Results of FMTs may also vary depending on the dosage of fecal matter that is 
transplanted. Research suggests that if patients did not respond to a lower dose of fecal 
transplant, increasing the dosage or performing the procedure again is beneficial and is 
significant in improving IBS symptoms (El-Salhy et al., 2019). Figure 2 shows that 
increasing the dosage of transplant material or simply performing the procedure again 
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improves many common IBS symptoms in 10 patients who did not respond to their first 
procedure. The research used a single superdonor for the FMT. 
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Figure 3: IBS Symptom Severity Score (IBS-SSS) with different common IBS 
symptoms following 30g of Fecal Microbiome Transplant (FMT) and 60g of FMT at 
o weeks, 2 weeks, 1 month and 3 months following the procedure.  A) overall IBS-
SSS B) Abdominal Pain C) Abdominal Distention D) dissatisfaction with bowel habits E)
Interference with quality of life. Results that were significant include IBS-SSS with 60 g 
FMT at 2 weeks, 1 month and 3 months, abdominal pain, abdominal distention and 
dissatisfaction with bowel habits following 60g FMT at 3 months. Figure from (El-Salhy 
et al., 2019). 
The results of FMTs also differ in respect to which symptoms are alleviated. For 
example, for most people who reported improvement in symptoms, not all of their 
symptoms improved. Most patients who underwent a specific FMT procedure reported 
alleviation of pain while others reported decreased bloating and still other reported 
decreased flatulence. These differences are due to both the donor’s and recipient’s 
microbiomes and the microorganisms within each microbiome (Pinn et al., 2014). 
Currently for IBS, the microorganisms that reside in the gut of a superdonor are still 
being elucidated. However, it is becoming clear that when these microorganisms are 
found and used in the FMT, the treatment is effective in improving IBS symptoms (Pinn 
et al., 2014)
Diet
The use of diet to treat IBS is becoming increasingly common as it has been 
shown that diet can directly affect the microbiome and thus many other mechanisms and 
symptoms in the body (David et al., 2014). There are many different diets that have been 
used for IBS, some general and some very specific for individual needs. Regardless of the
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diet, it has been shown that when IBS patients seek guidance for a diet specific to their 
individual needs, their symptoms improve. Thus, finding the unique diet for them, 
whether a popular diet or a very niche approach may improve their quality of life
(Østgaard et al., 2012). Due to the relatively inexpensive nature and minimal side effects 
of changing their diet, more and more IBS patients are moving towards this approach to 
manage their symptoms. 
One of the ways in which IBS manifests specifically for IBS-D has been 
elucidated in recent years and the mechanism provides some clarity as to how IBS can be 
treated. It has been shown that people who struggle with IBS-D have increased intestinal 
permeability. This increased permeability may be due to enteric pathogens in PI-IBS such
as C. difficile which alters the tight junctions in the small intestine leading to decreased 
integrity in the endothelium lining. Moreover, decreased permeability is present in IBS-C
(Barbara, 2006). The correlation between IBS-D symptoms and intestinal permeability 
can be seen in Figure 3 (Gecse et al., 2012).
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Figure 4: Colonic Permeability and Stool Frequency in IBS-D patients. The more 
permeable the colon is, the higher number of stools per week in patients with IBS-D. 
Figure from (Gecse et al., 2012).
This permeability can be altered more or less through the use of diet to either 
increase or decrease the severity of IBS symptoms. Patients with food allergies or 
sensitivities especially to gluten can exacerbate intestinal permeability which is thought 
to manifest via proliferation of mast cells. The change in number of mast cells and other 
inflammatory cells in subjects with IBS versus control subjects can be seen in Table 2
(Gecse et al., 2012).  Moreover, research suggests that while food intolerances are a main
symptom of all IBS subtypes and other functional GI disorders, food is not the cause of 
IBS. Therefore, whether the alteration in permeability of the GI tract is in response to 
food or causes the food intolerances is unknown. These food related symptoms such as 
bloating and abdominal pain have also been shown to be dose dependent (Barrett and 
Gibson, 2012). 
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Table 2: Changes in Mast Cell numbers in subjects with IBS versus control 
subjects.* 
*Also reported are the numbers on intraepithelial lymphocytes (another inflammatory 
marker) in IBS subjects versus control subjects. Table taken from (Gecse et al., 2012).
A common diet treatment for IBS patients is the low FODMAP diet in which, 
under the guidance of a doctor or health professional, IBS patients cut out food high in 
FODMAPs. The basis of this diet is that it is thought that IBS symptoms may be 
exacerbated by the fermentable short-chain carbohydrates (the FODMAPs). FODMAP 
stands for fermentable oligosaccharides, disaccharides, monosaccharides and polyols
(Halmos et al., 2014).  
Foods high in FODMAPS include foods high in fructose such as apples, onions 
and garlic. When ingested, these foods may cause bloating which is the result of 
increased water retention in the intestines and colon. In IBS-C patients, the fermentation 
of sugars caused a direct correlation between high methane gas levels during a breath test
and the amount of constipation they were experiencing. Figure 3 shows this correlation 
by graphing the amount of methane produced (from fermentable carbohydrates, 
FODMAPs) and the severity of constipation in 84 subjects. The results were significant 
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(r=0.6, p <.01). Moreover, a negative methane breath test indicated the fructose and other 
fermentable sugars are able to be absorbed and digested effectively thus not sensitive to 
FODMAPs (Chatterjee et al., 2007). Thus, when patients decrease the amount of 
FODMAPs ingested, bloating and other symptoms may abate as a result of decreased 
methanogens within the GI tract. 
Figure 3: Correlation between the amount of methane present in a breath test vs. 
Constipation severity in IBS-C patients. It is apparent that there is a significant 
correlation (r=0.6, p <.01) between the amount of fermentable carbohydrates (methane) 
and the amount of constipation present in IBS-C patients. Constipation was measured 
subjectively using a scale from 0-100 with 100 being the worst. 84 subjects were 
analyzed. Figure from (Chatterjee et al., 2007).
Due to the nature of FODMAPs and the symptoms they cause for IBS patients, it 
has been shown that it is beneficial to limit the amount of FODMAPs ingested in those 
who have fructose malabsorption (Shepherd et al., 2006).  However, if sensitive to 
FODMAPs at all, patients are usually only sensitive to the ones that are not digested 
14
properly. Moreover, recent research has shown that carbohydrate malabsorption is present
in healthy individuals and not just patients with IBS. However, what differs between the 
two sets of individuals is the altered gut flora in those with IBS making them 
hypersensitive to the malabsorption and thus causing IBS symptoms (Barrett et al., 2009).
There have been many research studies that focus on low-FODMAP diets in 
which patients reduce the number of FODMAP foods for different amounts of time and 
reintroduce them slowly. One such study compared this diet to a traditional IBS diet in 
which patients simply reduced the size of each meal, reduced the number of gas 
producing food consumed, and reduced fat, caffeine and insoluble fiber intake (Halmos et
al., 2014). The study found that both diets significantly improved IBS symptoms but that 
one diet did not prove to be more effective than the other. Figure 4 shows these results. 
Thus, simply reducing foods that are hard to digest may be what causes decreased IBS 
symptoms rather than specific fermentable sugars. 
Figure 4: Comparison of a low FODMAP diet and a traditional IBS diet with IBS 
symptom severity score at 3 different time points, day 0, day 14 and day 29. Both 
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diets showed reduced IBS-SSS but they did not differ significantly between one another. 
At day 29, there was a significantly significant reduction (p< .001) for both diets but 
there were differences between the diets. Figure from (Halmos et al., 2014).
Another common diet for patients with IBS is a gluten-free diet. The most 
common disease in which gluten is eliminated to alleviate symptoms is Celiac disease. 
Celiac disease is an autoimmune condition in which an individual will produce antibodies
to gluten and these antibodies will present in the small intestine. Celiac patients’ bodies 
will then mount an immune response towards the small intestine and cause various 
uncomfortable and painful symptoms. Thus, those with Celiac disease eliminate gluten 
from their diets to maintain a positive quality of life. Moreover, it is proposed that those 
with IBS test positive from Celiac disease more than those without IBS (Schuppan, 
2000). 
There is recent evidence of a new subgroup of IBS patients, those with non-celiac 
gluten sensitivity (NCGS) (Fasano et al., 2015). Moreover, this subgroup can be of any 
type of IBS and exhibit similar symptoms to those with Celiac disease such as bloating, 
gas, diarrhea and headaches upon consuming gluten. This subgroup of patients is best 
treated with dietary intervention. A recent study on 34 IBS patients showed a significant 
decrease in quality of life as well as increased IBS symptoms upon eating gluten. After 
decreasing amounts of gluten consumed, IBS symptoms severity decreased and quality of
life increased. Figure 5 shows the differences in symptom severity for patients eating 
gluten vs. placebo subjects over a 6 week time period (Biesiekierski et al., 2011).
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Other dietary protocols that are popular among those who are diagnosed with IBS 
are increasing consumption of soluble fiber and homeopathic remedies such as 
peppermint oil and ginger. Dietary fiber is frequently dichotomized into insoluble and 
soluble fiber based on their actions in the body. Insoluble fiber forms a structural matrix 
whereas soluble fiber forms a gel in the gut which may improve digestion (Aller et al., 
2004). 
Figure 5: Change is symptom severity between gluten-eating subjects and placebo 
subjects over a 6-week period. Symptoms severity changes between week 1 and week 6 
were significantly different among overall symptoms, pain, bloating, satisfaction with 
stool consistency and tiredness. The difference in wind and nausea were not statistically 
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significant. The difference between the two group were statistically significant in pain, 
bloating, satisfaction with stool consistency and tiredness but not with overall symptoms, 
wind and nausea. Figure from (Biesiekierski et al., 2011).
The most popular soluble fiber that is used to treat IBS symptoms (both IBS-C 
and IBS-D) is psyllium husk fiber. One study found that while psyllium husk did not 
significantly alter quality of life, it did lessen symptom severity as compared to those 
who took the placebo or had insoluble fiber (bran) (Aller et al., 2004). Moreover, because
soluble fiber creates a gel within the gut, this bulks up the stool and allows it to pass 
through the digestive tract quicker and more efficiently and thus provides a benefit for 
those especially struggling with IBS-C  (El-Salhy et al., 2017). A systematic review of 17 
papers on the use of soluble and insoluble fiber for treating IBS found that soluble fiber 
significantly improved symptoms in those with IBS as compared to placebo patients 
whereas insoluble fiber had no significant effect (Bijkerk et al., 2004). 
Peppermint oil is an herbal remedy that has been shown to relax smooth muscle in
the GI tract by decreasing calcium channel action (Hills and Aaronson, 1991). This effect 
has been shown to significantly decrease pain and other symptoms such as bloating in 
those with IBS (Merat et al., 2010).  Because peppermint oil is all natural and does not 
require a prescription, this makes it a very attractive treatment for IBS. Moreover, 
because it addresses the pain associated with both IBS-C and IBS-D, peppermint oil can 
be used for all subtypes of IBS. 
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Probiotics 
The use of probiotics and their effects on not just IBS but many other illnesses 
and conditions is very well documented (Guandalini, 2011). Probiotics as a treatment for 
all subtypes of IBS are becoming one of the most popular treatments perhaps because of 
the research documenting their benefits. Probiotics are essentially live microorganisms 
encapsulated into a pill or liquid form that produce a beneficial effect on the host that 
ingests them. Because IBS, whether post-infectious or not, is characterized by a change in
beneficial and nonbeneficial microorganisms that reside in the gut, supplementing with 
these beneficial microorganisms to replenish the gut may be helpful in reducing IBS 
symptoms (Zhang et al., 2016). 
There are a few different theories as to how probiotics specifically improve 
symptoms in those with IBS. One theory is that probiotics enhance and alter immune 
functions and allow for antibacterial and antiviral properties in the gut (Isolauri et al., 
2002). Another theory suggests that probiotics decrease the inflammation within the GI 
tract, a hallmark in the pathogenesis of IBS (O’Mahony et al., 2001).  Figure 6 shows the
rationale behind probiotics and their beneficial effect of restoring the gut microbiome to 
normal levels following some sort of a controllable and/or uncontrollable factor.  
19
Figure 6: The role probiotics play to bring the gut microbiome back to homeostasis 
following exposure to internal and external stressors. Probiotics reinstates the gut 
microbiome to normal levels. Stressors that can shift the levels of microbiota include 
uncontrollable factors such as genetic factors and controllable factors such as diet, 
immunity and inflammation and GI stressors. The role of probiotics is to restore the 
microbiome to homeostasis following any of these stressors by introducing beneficial 
bacteria into the damaged microbiome. Figure from (O’Mahony et al., 2001).
Because each individual’s gut microbiome is completely different, the strain of 
probiotics and the amount needed should be unique to each patient who chooses to use 
them. Many strains of microorganisms within probiotic supplements have been studied 
but perhaps the most extensively studied are Lactobacillus and Bifidobacterium infantis. 
In a study comparing these two strains of probiotics, researchers determined that in 
comparison to Lactobacillus and placebo subjects, B. infantis significantly reduced 
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common IBS symptoms such as abdominal bloating and pain (O’Mahony et al., 2005). 
Moreover, researchers were able to show that the mechanism in which B. infantis was 
able to alleviate IBS symptoms was through the restoration of the ratio of IL-10/IL-12. At
baseline, this ratio was elevated which is a hallmark of a proinflammatory state. 
However, after treatments with B. infantis, the ratio was significantly reduced as 
compared to subjects treated with Lactobacillus and placebo pills. Thus, this finding is 
evidence that B. infantis works through lowering the inflammation in the gut following 
the onset of IBS (O’Mahony et al., 2005).  Figure 7 shows the effects of B. infantis in 
increasing the IL-10/ IL-12 ratio in those with IBS. 
Figure 7: The effect of B. infantis on the ratio of IL-10/IL-12, an inflammatory 
marker in the gut. Compared to both the lactobacillus (L.salivarius 4331) strain and the 
placebo pill, treatment with B. infantis was statistically significant in increasing the ratio 
and thus decreasing inflammation in patients with IBS. The baseline ratio for those with 
IBS were much lower pre-treatment compared to healthy volunteers. Figure from
(O’Mahony et al., 2005).
21
Many studies have been done on patients with diarrhea associated with diseases 
other than IBS treated with Lactobacillus, another commonly studied probiotic strain. 
One such study has shown that it decreases diarrhea significantly in young malnourished 
African children (Oberhelman et al., 1999). Therefore, researchers propose this strain 
may be beneficial in treating IBS and particularly IBS-D. Another similar study showed 
that with various strains of Lactobacillus, diarrhea was prevented and decreased in 
infants with rotavirus due to increased adhesion of probiotics to intestinal mucus. The 
researchers hypothesize this adhesion made the probiotics more potent. The researchers 
concluded that this adhesion may increase immune functions but further research is 
necessary to make any correlations (Juntunen et al., 2001). Nevertheless, these research 
studies, although not on patients with IBS, provide evidence of the beneficial effects of 
the probiotic strain Lactobacillus especially for those with diarrhea. 
Many probiotics are mixtures of various strains of gut microorganisms and the 
research on these also show they are beneficial in alleviating the symptoms of IBS. One 
such study showed that a probiotic pill with strains of Bifidobacterium longum, B. 
bifidum, B. lactis, Lactobacillus acidophilus, L. rhamnosus and Streptococcus 
thermophilus significantly reduced painful IBS symptoms such as bloating and 
abdominal pain by altering the gut microbiota as compared to those taking placebo pills
(Cha et al., 2012). In essence, these studies show that because each individual has a 
unique microbiome and unique IBS symptoms, one or more strains of probiotic may be 
beneficial for them while others may have no effect. 
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Antibiotics and Antidepressants
Compared to other treatments for IBS, antibiotics and other medicines have not 
been used as frequently due to side effects, cost and potential for antibiotic resistance. 
However, there have been some studies on various medical interventions including 
antibiotics and antidepressants to treat both IBS-C and IBS-D. The most commonly 
prescribed and the most studied antibiotic for IBS is Rifaximin. Previously used for 
traveler’s diarrhea, Rifaximin has proven effective in decreasing diarrhea and symptoms 
associated with it such a dehydration and bloating (Rivkin and Gim, 2011). Rifaximin 
targets only the gut and is predominately non-absorbable which decreases its ability to 
confer resistance and also decreases the severity and number of side effects. There are 
many thoughts on how Rifaximin works but the main thesis is that it works by inhibiting 
gut bacterial gene expression and thus works best on those whose IBS is characterized by
an increase in harmful gut microbiota (Li et al., 2016). 
Many studies have shown that Rifaximin is significantly beneficial in reducing 
many symptoms in those diagnosed with IBS. One such study found that Rifaximin 
decreased both flatulence and abdominal bloating compared to those who took the 
placebo. The decrease in these symptoms were found to correlate with a decrease in the 
amount of hydrogen measured in a breath test (Shahara et al., 2006). As explained above, 
measurements of hydrogen and methane in a breath test correlate with the number of 
certain types of harmful bacteria in the GI tract which is a common symptom in those 
with IBS. Moreover, Rifaximin was shown to decrease other IBS symptoms such as pain,
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urgency and stool consistency significantly compared to those who took a placebo pill. 
Whether these results were due to decreased harmful gut microbiota or decreased 
immune response is unknown, however there was shown to be a decrease in 
uncomfortable IBS symptoms in those with IBS-D only (not IBS-C) (Pimentel et al., 
2011).  Figure 8 shows the decrease from baseline of symptoms associated with IBS.  
However, Rifaximin was shown to only be effective for up to 10 weeks post-antibiotics 
and thus may not be beneficial for long-term symptom maintenance (Pimentel et al., 
2006).
Figure 8: Percent relief from IBS symptoms for those who took the antibiotic 
Rifaximin vs. those who took a placebo pill. There was a significant difference between
the two populations in this study (P=0.001). Therefore, it was shown that compared to the
placebo pill, Rifaximin significantly decreased IBS symptoms in those without IBS-C. 
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The amount of relief decreased steadily past 2 weeks after taking the dosage of antibiotics
and therefore may only be effective for a certain amount of time. Figure from (Pimentel 
et al., 2011).
Recently, antidepressants and more specifically, tricyclic antidepressants (TCAs) 
and serotonin selective reuptake inhibitors (SSRIs) have been used to treat those with 
IBS. (Crowell et al., 2004). TCAs have been studied more in terms of their effects on IBS
than SSRIs. 
One TCA that has been studied is amitriptyline. While most studies on the effect 
of amitriptyline are inconclusive due to patients’ inability to finish the study or low 
sample number, they do show promising results for patients with IBS-D in particular. The
main complaint from those who have taken TCAs for IBS is that they may increase 
constipation and thus are not ideal for IBS-C. One such study concluded that 
amitriptyline significantly lowered IBS-D symptoms in 50 patients compared to those 
who were given the placebo over the span of 2 months (Iskandar et al., 2014). Table 3 
shows the results of the study in which there was a significant decrease in common IBS-
D symptoms for those who took amitriptyline compared to those who were given the 
placebo. 
Currently amitriptyline is thought to exert its effects by increasing the threshold of
pain in the central nervous system when the stomach is distended and thus decrease 
visceral hypersensitivity, a hallmark symptom of those with IBS. Essentially, TCAs alter 
the gut- brain axis and are especially beneficial in those who have a comorbidity of IBS 
and depression (Gorelick et al., 1998). Other TCAs such as nortriptyline are thought to 
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have similar effects to amitriptyline but at different dosages and individuals may be more 
susceptible to one but not another TCA and thus the medicine is individual like most 
other IBS treatments (Iskandar et al., 2014).
Table 2: Changes among IBS patients given the TCA, Amitriptyline and those who 
were given the placebo pill.* 
















































































































2.4 2.5 1.6* 1.2* 1.6* 0.5*
*The results show there were significant changes in regards to flatulence, diarrhea and 
number of symptoms for those who took the placebo pill at the end of the first month. 
Those who were given amitriptyline also had significant changes at the end of the first 
month for changes in loose stool, overall symptoms and abdominal pain. For the second 
month, those who took the placebo pill saw significant changes in abdominal pain, 
flatulence, loose stool, diarrhea and number of symptoms. For the those who took 
amitriptyline, symptoms that were significantly different were pain, incomplete 
defecation, loose stool, diarrhea and number of symptoms. Table from (Vahedi et al., 
2008).
Serotonin is an important neurotransmitter that is used in many different 
biological processes and is very prevalent in the gut. Serotonin’s signaling pathway is 
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thought to be involved in the pathophysiology of IBS-C and IBS-D. Thus, manipulating 
various parts of this pathway may be beneficial in the relief of IBS symptoms. 
Essentially, serotonin increases gut motility through a variety of mechanisms and gut 
motility can increase through multiple steps of the serotonin signaling pathway. The 
pathway consists of many signaling steps and ultimately ends by acting on multiple 
receptors. Serotonin reuptake transporter (SERT) inactivates and takes up excess 
serotonin so it does not exert extra effects in healthy individuals. This particular molecule
is implicated in IBS pathophysiology and is a target of some IBS drugs. Moreover, 
serotonin exerts both excitatory effects which causes smooth muscle contraction via 
acetylcholine release and inhibitory effects in which it elicits nitric oxide release and 
subsequently smooth muscle relaxation (Sikander et al.,  2009).  Figure 9 shows 
serotonin’s signaling pathway. 
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Figure 9: Serotonin signaling pathway. 5-HT refers to the serotonin molecule. The 
pathway starts when enterocytes are stimulated by pressure. Serotonin is then released 
from enterochromaffin cells (EC) in the small intestine. 5-HT then acts on both extrinsic 
and intrinsic pathways. The extrinsic pathways go to the brain stem and spine. The 
extrinsic pathway stimulates various CNS responses such as satiety and abdominal pain. 
When the intrinsic targets (IPANs) are stimulated, they elicit their effects by modulating 
gut motility, secretion of enzymes and intestinal vasodilation. IPANs are located both in 
the myenteric plexus and submucosal plexus within the small intestine and release 
different signaling molecules which leads to different effects. SERT will inhibit excess 5-
HT from stimulating excess effects. Figure from (Sikander et al., 2009).
There are various medicines that take advantage of the serotonin signaling 
pathway and one such medicine is Alosteron, a 5HT3 antagonist. This medicine 
selectively inhibits 5HT3, a serotonin receptor. Alosteron has been shown to decrease 
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visceral hypersensitivity when studied on women with IBS. When compared to those give
the placebo pill, subjects with IBS-D or IBS-M who were given Alosteron showed a 
significant decrease in IBS related abdominal pain, defecation urgency, defecation 
frequency and improved stool consistency. However, no significant results were shown 
with men which may lead to a need for more research on this particular receptor
(Camilleri et al., 1999). Moreover, another medicine that is also a 5HT3 antagonist, 
Ondansetron, is effective in decreasing defecation urgency and inducing mild 
constipation in men. Because of its effects, Ondansetron may be beneficial in men with 
IBS-D (Talley et al., 1990). Thus, the 5HT3 receptors are just one step in the serotonin 
signaling pathway that is manipulated in the treatment in IBS. Like many of the other 
treatments, these drugs are specific and the reason why they work in some patients and 
not others are unknown. Nevertheless, these drugs have shown significant results with 
lessening major IBS symptoms and may be a viable option for those with IBS-D or IBS-
M.
Various medicines that exert effects on the serotonin pathway have been used to 
alleviate IBS symptoms due to their mechanisms of action. SSRIs are one category of 
such medicine. They tend to be more beneficial for those with IBS-C because they inhibit
SERT and therefore allow serotonin to remain active longer. In theory, this mechanism 
will increase gut motility. However, there are mixed results with SSRIs as therapies for 
IBS. 
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Fluoxetine, an SSRI has been studied as a potential drug for those with IBS-C in 
particular (Iskandar et al., 2014).  When studied in comparison to a placebo, was shown 
in one study to have significant effects in reducing abdominal pain and bloating and 
increasing gut motility (Vahedi et al., 2005). Figure 10 shows the results of this study and
reveals the significant changes in IBS-C symptoms for those who took Fluoxetine 
compared to those who took the placebo. However, another study on this particular drug 
showed that while it slightly decreased uncomfortable side effects in those with IBS-C, it 
did not show significant benefits. Although not significant, this study did show promising
results in regards to decreasing abdominal pain but the sample size was too small to make
any real conclusions (Kuiken et al., 2003). Thus, while there may be significant benefits 
for some, there is inconclusive evidence to determine whether Fluoxetine is an effective 
treatment against IBS-C symptoms. 
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Figure 10: Comparison of symptoms between those who took Fluoxetine and those 
who took the placebo pill for 16 weeks. The greatest results were seen between the 4- 
6week mark and were consistent until the termination of the study at 16 weeks. 
Significant results were seen for symptoms of abdominal pain, bloating, and stool 
consistency. The patients in this study were predominately those with IBS-C. The 
mechanism of action for Fluoxetine is still undiscovered. Figure from (Vahedi et al., 
2005).
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Another SSRI, Citalopram, like Fluoxetine, shows variable results among 
research studies. For example, in one such study on non-depressed IBS patients, 
Citalopram showed no significant benefits. While there were small effects, there were no 
statistically significant effects between those who took the drug and those who took the 
placebo (Ladabaum et al., 2010). However, another study on 23 non-depressed IBS 
patients showed that compared to placebo, subjects, those who took Citalopram saw 
significant results in terms of decrease of IBS symptoms such as abdominal pain (Tack et 
al., 2006). Thus, like the other medicines used for IBS, Citalopram shows potential to 
treat some patients but not all. The treatment may be selective towards people with 
specific symptoms and IBS subtypes and thus are not beneficial for all. In terms of 
medications, there is more conclusive evidence that TCAs show significant benefits 
compared to SSRIs when treating IBS. Because TCAs are more often used to treat IBS-D
due to the possibility of constipation, other medicine may need to be researched for the 
treatment of IBS-C. 
Psychological Treatments
In recent years, there has been an increase in treatments for many diseases that 
increase mindfulness and relaxation and confer psychological interventions. The thought 
behind these treatments for IBS in particular is that IBS symptoms may increase in 
response to stress and anxiety and thus using practical interventions may lessen these 
symptoms. The gut-brain axis is a large area of research as it pertains to IBS. Essentially, 
the brain and its related structures receive input from the gut and the external 
environment and combines these inputs to send signals back to the gut to maintain GI 
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homeostasis (Quigley, 2018). When the homeostasis is disturbed, common IBS symptoms
such as bloating, pain and changes in defecation pattern occur. Thus, the way the brain 
and the gut communicate is essential in maintaining a healthy microbiome, immune 
system and other GI processes. Figure 11 shows the ways in which the brain and the gut 
interact. 
Figure 11: Brain-gut axis. There are bidirectional signals between the gut and the brain. 
The brain feeds into the gut via the parasympathetic (PSNS) and sympathetic (SNS) 
pathways and also through the hypothalamus, pituitary axis (HPA) via hormones. The gut
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gives the brain feedback and the brain also reacts to outside stimuli such as stress as well.
This signaling affects many systems in the body such as the immune system and 
homeostasis in the gut. When this axis is off, homeostasis is off as well and can lead to 
many IBS symptoms and thus the gut-brain axis is one of therapeutic benefit. Figure from
(Quigley, 2018).
There are many psychological therapies used to treat those with IBS which utilize 
the gut-brain axis. One such therapy is Cognitive Behavioral Therapy (CBT). CBT is a 
therapeutic approach that employs multiple techniques to help alleviate IBS symptoms. 
These techniques include psychoeducation, relaxation, cognitive restructuring, problem-
solving skills and exposure techniques. Psychoeducation refers to educating the patient 
with information on IBS such as the gut-brain axis and ways in which their symptoms 
can manifest. Relaxation refers to using various breathing techniques in order to bring 
awareness to breath and decrease stress contributing to symptoms. Cognitive 
restructuring is the process in which the patient learns to identify awareness of symptoms 
and stress related to IBS symptoms. Problem-solving skills refers to teaching the patient 
how to cope with stressors and how to solve them without increasing symptoms related to
stress. Lastly, exposure techniques allows the patient to come into contact with IBS 
related fears such as not having a bathroom or having symptoms at an inopportune 
moment (Kinsinger, 2017).
Studies on CBT as a treatment for IBS show generally beneficial effects in terms 
of decreasing symptoms for all subtypes of IBS (Kinsinger, 2017). One study which had 
8 subjects saw a significantly decreased amount of visceral hypersensitivity following 
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CBT with trained therapists. Although the decrease in visceral hypersensitivity was 
statistically significant, changes in bowel habits were not and thus, the researchers 
hypothesized that perhaps CBT only alters cognitive appraisal of visceral hypersensitivity
and thus lowers abdominal pain in those with IBS (Boyce et al., 2016). The way in which
these researchers determined CBT to work in those with IBS is seen in figure 12. 
Figure 12: The relationship between IBS symptoms, visceral hypersensitivity and 
cognitive response and appraisal. The model proposes that although visceral 
hypersensitivity may be caused by genes, anxiety and other stressors can cause it to 
increase. Thus, using therapies such as CBT may allow the patient to learn how to 
respond to the visceral hypersensitivity and lessen the IBS symptoms. CBT relies on the 
gut-brain axis to decrease common IBS symptoms such as visceral hypersensitivity. 
Figure from (Boyce et al., 2016).
The way in which CBT mediates its results is still being debated. One study 
concluded that the positive effects that CBT has on IBS symptoms is completely 
independent of the stress and anxiety the patient may feel. Instead, they proposed that the 
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improvement in IBS symptoms has to do with the increase in quality of life the patient 
feels post-CBT with a trained therapist. Thus, regardless of whether or not the IBS patient
is in a state of distress, CBT can decrease their symptoms by increasing their quality of 
life (Lackner et al., 2007). The increase in quality of life in these patients may be due to 
any of the techniques CBT employs and may also explain why visceral hypersensitivity 
was shown to decrease but stool variability was not. 
Moreover, not all therapists are certified in providing CBT and thus the demand 
for appropriately trained therapists is increasing. As technology is also evolving, it has 
also been proposed to give IBS patients successful CBT via internet feedback and email 
with a certified CBT therapist. One study on this proposed mechanism of care showed 
that when using this internet based therapy, certified CBT therapists were able to 
significantly reduce various IBS symptoms such as visceral hypersensitivity by 
employing the successful techniques of CBT such as stress management and exposure 
techniques (Hunt et al., 2009). Thus, as CBT becomes more popular, it may become a 
more attractive option for IBS care due to the lack of side effects and no real risks 
especially if patients are able to receive the treatment from anywhere. 
CBT is not the only psychological intervention for those with IBS. A related but 
different therapy is relaxation therapy. This therapy teaches those with IBS how to 
manage their symptoms through studied relaxation techniques. While relaxation is one of 
the tenets of CBT, it can be employed on its own. When taught by trained therapists, IBS 
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patients were able to decrease the severity of their symptoms. The thought behind these 
results is that relaxation training decreases the muscle tension in the abdominal and will 
thus decrease related IBS symptoms. Abdominal pain in general has been shown to 
increase muscle tension. Decreasing the muscle tension by using relaxation treatment can
decrease the abdominal pain associated with many IBS symptoms. The relaxation 
techniques that the IBS patients were taught were shown to be easily employed in 
stressful situations that could increase symptoms (Veek et al., 2007). Figure 13 shows the
decrease in IBS symptoms following relaxation therapy compared to those who sought 
traditional medical treatments for their symptoms. Thus, even without employing all of 
the CBT techniques, just using one may help those with certain IBS symptoms especially 
visceral hypersensitivity. 
Figure 13: Comparison of severity of IBS symptoms between relaxation therapy 
(RT) and traditional medical interventions at 0,3,6, and 12 months. The difference 
between the severity of symptoms at the beginning of RT and at 12 months was 
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statistically significant (P=.002). The difference for traditional medical intervention was 
not significant. Figure from (Veek et al., 2007).
Another IBS treatment that employs the gut-brain axis is gut-directed 
hypnotherapy. Hypnotherapy was first documented in 1984 by P.J. Whorwell and his 
team when he used hypnotherapy, psychotherapy and placebo treatments on 30 patients 
with IBS (Whorwell et al., 1984). Compared to other treatments, hypnotherapy was the 
most beneficial and there were significant differences between the various therapies and 
their corresponding efficacies. Moreover, there was little to no recurrence of symptoms 
three months after the hypnotherapy treatment (Whorwell et al., 1984). As described by 
Whorwell in a follow-up study, the hypnosis included explaining the physiology of the GI
system followed by “standard deepening procedures” in which the patient was under true 
hypnosis. The patient was then told to feel the warmth on their abdomen and relate it to 
the efficiency of their digestive system. Essentially, while under hypnosis, the patients 
were taught to believe that their GI tract was functioning normally. The first two sessions 
were done in person and then the sessions were done through the use of a recorded tape
(Whorwell et al., 1987). Thus, without access to a certified hypnotherapist, IBS patients 
may use tapes to decrease their symptoms. 
Since the first uses and documentation of hypnotherapy, there have been many 
studies on hypnotherapy and its benefits for those with IBS. In study on children with 
IBS and other related gut issues, hypnotherapy was shown to be statistically significant in
decreasing many aspects of the IBS including abdominal pain and frequency of pain 
compared to those who were treated by standard medical techniques (SMT) (Vlieger et 
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al., 2007).  Figure 13 and Figure 14 show these changes and the differences between 
SMT and hypnotherapy when used to treat children with IBS and other related gut issues.
Figure 14: Pain Intensity for Hypnotherapy (HT) treatment vs. Standard Medical 
Treatment (SMT) for 1 year for children IBS patients. The pain intensity significantly 
decreased in the HT treatment throughout the year and compared to the SMT. Both 
groups started at high pain intensities and by the end of the year, the HT treatment had 
virtually no pain intensity. The treatment continued for 3 months and during those 3 
months, the pain intensity significantly decreased but it also continued to decrease at the 
follow ups at 6 months and 12 months. Figure from (Vlieger et al., 2007).
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Figure 15: Pain frequency for Hypnotherapy (HT) treatment vs. Standard Medical 
Treatment (SMT) for 1 year for children IBS patients. The pain frequency for the HT 
treatment significantly decreased during the 3-month treatment phase compared to the 
beginning of the treatment as well as compared to SMT. The pain frequency was also 
shown to continue to decrease at the 6 month and 12 months follow ups. The pain 
frequency decreased to almost nothing by the 1year mark following HT treatment. 
However, following SMT the patients had very little decrease in pain intensity. Figure 
from (Vlieger et al., 2007).
Because hypnotherapy has been shown to be successful at treating those with IBS 
symptoms especially those with pain associated with their IBS, some studies have aimed 
at elucidating the mechanism of hypnotherapy and why it works for some with IBS. One 
such study proposed that hypnotherapy does not change anything physiologically and 
instead changes psychological and somatic functions in the body (Palsson et al., 2002). 
For example, according to the study, there were no changes in common physiological 
issues associated with IBS such as rectal smooth muscle tone but there were decreases in 
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stress and anxiety both related to IBS and life in general and thus is thought to decrease 
IBS symptoms (Palsson et al., 2002).
Future of IBS treatments
As more is known about the pathophysiology of all subtypes of IBS, there are 
new options for treatment. While some of these options build upon current treatments, 
others are completely novel and show promising results. While there has been a lot of 
research on probiotics, prebiotics and symbiotics are also currently available as 
treatments for IBS but there is not as much research on the efficacy of them. While 
probiotics are live microorganisms within the gut, prebiotics are food for these 
microorganisms that are not able to be digested but promote the growth of various 
bacteria within the gut. Symbiotics are a mix of both probiotics and prebiotics and thus 
contain the live microorganisms and the material to promote their growth. They may be 
effective for those who do not respond to either probiotics or prebiotics alone (Salminen 
et al., 1998).  
In a study comparing the use probiotics alone (providing IBS patients yogurt with 
probiotic strains) with providing IBS patients with probiotics and prebiotics (probiotic 
yogurt with acacia fiber, a prebiotic supplements) those who had both prebiotics and 
probiotics saw greater benefits in reduction of symptoms than those who just had the 
yogurt (Min et al., 2012). Therefore, because prebiotics and probiotics make up the 
symbiotic supplement, there is promising research on this supplement for treatment of all 
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subtypes of IBS rather than just using probiotics. Figure 16 shows the results of treating 
IBS patients with a symbiotic. The results of this study were statistically significant and 
show a promising future for the use symbiotic supplements on those with IBS (Dughera 
et al., 2007).
Figure 16: Change in abdominal pain and bloating following the administration of a
symbiotic supplement at different time points. The difference from T0 to T2 was 
statistically significant (P< .0001). Both the abdominal pain and bloating were high at the
start of the study and using the symbiotic supplement, these measures were both lowered 
in patients with IBS. Figure from (Dughera et al., 2007). 
Perhaps the newest and most upcoming treatments for all subtypes of IBS deals 
with bio-individuality, a term coined to encompass the idea that because each 
microbiome and body is different, treatment for diseases should also be different. Thus, 
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no one treatment is beneficial for a whole population of people. Since the completion of 
the human genome project in 2003, research on individualized medicine has been at an 
all-time high (Green and Guyer, 2011).  However, because this field is so new, it has been
met with many challenges including but not limited to cost, technological barriers, and 
regulation.
Recently there has been a specific clinic dedicated to researching and 
implementing individualized medicine in a clinical setting. This clinic is under the 
supervision of the Mayo Clinic and is called the Center of Individualized Medicine 
(CIM). CIM aims to make unique treatments based on individuals’ genomes 
commonplace. The implications for this type of individualized care are to decrease 
possible side effects, decrease amount of medications taken by an individual and allow 
for all around care to be more effective and less stressful (Lazaridis et al., 2014). Figure 
17 shows the goal of the CIM for the future of medicine.  There is still a lot of research to
be done in this field but it shows promising results for future medicine and treatments for 
many diseases including IBS. 
A lot of research is being done on individualized medicine and its implications for
a range of treatable diseases including IBS. One such study researched microRNA 
(miRNA) polymorphisms and their implications for medical treatments unique to a 
specific individual and their individualized needs.  MiRNAs are small conserved sections
of non coding RNA. It has recently been found that miRNAs can have polymorphisms 
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and these sequences in conserved regions of RNA are unique to specific diseases. Thus, 
these changes in DNA may help to elucidate unique treatments for diseases (Green et al., 
2011). For example, it was found that in patients with intestinal atrophy from 
Helicobacter pylori, a serious stomach infection, there was a polymorphism found in 
miR-27a region. The idea behind this finding was that this unique section of RNA may be
used as a pharmacological target in those found to have this polymorphism (Otsuka et al.,
2018).  
Figure 17: Converting genotypic data into clinical treatments for a range of diseases.
The CIM’s aim is to collect data on a individual’s unique genome and use that 
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information to create individualized treatments for their symptoms and diseases. Figure 
from (Lazaridis et al., 2014).
There is still a need for more research to be done on the topic of individualized 
medicine but the crux of this method of treatment has shown real promise especially for 
those with treatable disease such as IBS. In upcoming years, this type of medicine may 
become more widely used as research elucidates its efficacy on specific diseases. 
However, as of today, there is not enough evidence to make any conclusions. 
Final Conclusions
As more has been discovered about the causes and symptoms of all subtypes of 
IBS, more and more acceptable and efficacious treatments are being elucidated and 
implemented. This trend will no doubt continue in the upcoming years as more research 
on the gut-brain connection is being established and individualized medicine becomes 
more commonplace. Moreover, as the current treatments and new revolutionary treatment
options such as FMT are researched more, they may become more efficacious in 
improving IBS symptoms.
Due to the individual nature of diet and specific food intolerances, specific diets 
have been shown to be effective for those with IBS. These diets are especially effective 
when patients are able to recognize their specific food intolerances and eliminate them. 
However, these diets can become less beneficial when they recommend cutting out many 
foods and thus do not allow the microbiome to flourish off nutrients. Like many of the 
other treatments suggested for those with IBS, diets are incredibly unique to individuals 
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and patients should work with health professionals to decide which diet may work for 
them.
Although new, FMTs have a promising future in being an effective treatment for 
those with IBS due to their nature of reintroducing a healthy gut microbiome to those 
with diminished or unhealthy microbiomes. Because of the vast amount of research 
suggesting altered microbiomes in those with IBS, this treatment may become 
commonplace when specific “super donors” are recognized.  
There is room for more research for many of the treatments used today for IBS 
including probiotics and other supplements. Because of the shear amount of supplements 
offered today for a wide array of symptoms, those with IBS may have a hard time finding
what works for them. Thus, training competent medical professionals and having 
appropriate microbiome testing is vital to increase the efficacy of specific treatments. 
Because the microbiome is so unique and individual, elucidating specific gut microbes 
through microbiome testing may increase the ability to prescribe medicines more 
effectively. 
Perhaps the most universally beneficial treatments for IBS deals with the gut-
brain axis as it has been shown that in those with IBS, the gut-brain axis is affected 
especially when dealing with stress. As discussed above, these treatments deal with many
aspects of mental health and are very beneficial when implemented correctly. Like the 
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other treatments, trained health professionals are crucial for success in psychological 
treatments. However, as the treatments become more widely accepted as beneficial 
treatments, more and more people may become trained to help these patients in 
treatments such as CBT and hypnosis. 
Because of the current research on bio-individuality and individualized medicine, 
IBS treatments should become more tailored to each person’s unique microbiome so that 
no two patient’s treatment plans are the same. As discussed in the literature, the main 
difficulty on finding the most efficacious treatment for IBS is that no one treatment can 
be a universal fix for patients. Thus, tailoring the specific treatments to patients may be 
the future of not just IBS treatment but for many other diseases as well. The future of IBS
treatments is exciting due to the current research on the individual treatments and in a 
few years, it may be possible that each patient’s treatment is able to be completely 
tailored to them. In the meantime, the established treatments have been shown to be 
beneficial in many patients and thus, patients should consult their health professionals to 
determine their best treatment options. 
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